Meeder Asset Management Inc Clovis Oncology, Inc. Transaction History

Meeder Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$5.69 - $9.69 $1,405 - $2,393	-247 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$3.77 - $11.0 $52 - $154	-14 Reduced 5.36%	247 $2,000
Q4 2019 Feb 13, 2020	SELL	$3.0 - $16.43 $972 - $5,323	-324 Reduced 55.38%	261 $3,000
Q3 2019 Oct 17, 2019	BUY	$3.93 - $15.35 $1,300 - $5,080	331 Added 130.31%	585 $2,000
Q2 2019 Aug 05, 2019	BUY	$12.81 - $25.67 $2,613 - $5,236	204 Added 408.0%	254 $4,000
Q1 2019 Apr 16, 2019	SELL	$17.66 - $30.28 $6,198 - $10,628	-351 Reduced 87.53%	50 $1,000
Q4 2018 Jan 17, 2019	BUY	$11.63 - $32.67 $4,663 - $13,100	401 New	401 $7,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.